Efficacy of a New Composition (BU002) for Debridement of Chronic Cutaneous Ulcers
New Product for the Simple, Rapid, and Effective Debridement of Skin Ulcers
This study is testing a new liquid treatment for people with long-lasting (chronic) wounds, such as venous leg ulcers or diabetic foot ulcers. These wounds can be difficult to heal because they often contain dead tissue and bacteria. The new product is designed to help clean the wound and remove dead tissue, which may help the wound heal better. It will be compared to a commonly used treatment called Polyhexanide gel.
About 80 people aged 60 years or older will take part in this study. Each participant will be randomly assigned (like flipping a coin) to receive either the new treatment or the standard treatment. Neither the participant nor most of the study team will know which treatment is being used during the study to ensure fair results.
The study will last 4 weeks. Participants will attend eleven visits at the wound care center. During these visits, trained nurses will clean and treat the wound. The study team will:
- Measure the size of the wound
- Take small samples from the wound to check for bacteria
- Ask questions about pain and general health
- Check blood flow in the legs
- Perform blood tests at the beginning A specialist doctor will examine the wound at the start and at the end of the study to see how it has improved.
Overall, this study aims to find out if the new treatment can help wounds heal better and more quickly than current standard care.
Taking part in the study is completely voluntary. Participants can leave the study at any time without affecting their usual medical care. All personal and medical information will be kept confidential.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: María B Olivares, PhD
- Numéro de téléphone: 3634 562223279634
- E-mail: molivares@udd.cl
Lieux d'étude
-
-
Metropolitana de Santiago
-
Santiago, Metropolitana de Santiago, Chili
- Recrutement
- Universidad del Desarrollo
-
Contact:
- María B Olivares, PhD
- Numéro de téléphone: 3634 562223279634
- E-mail: molivares@udd.cl
-
Chercheur principal:
- Daniela Constanza Espinoza, Nurse
-
Sous-enquêteur:
- Isabel Aburto, Nurse
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria
A pure or mixed venous ulcer, or a diabetic, neuropathic, or neuroischemic foot ulcer, greater than or equal to 4 cm² and less than or equal to 30 cm² with critical colonization.
A duration of the ulcer greater than or equal to 2 months and less than or equal to 2 years.
Age over 60 years: due to the higher prevalence of ulcers in adults over 60 years of age.
An ankle-brachial index between 0.6 and 1.3.
Exclusion criteria
Morbid obesity (BMI > 35)
History of cancer treatment in the last year
Uncontrolled diabetes (Glycated Hemoglobin above 10 mg/dL)
Uncontrolled hypertension (blood pressure readings greater than 140/90 mmHg)
Patients with a known allergy to the components of the products under study.
Patients with signs of infection or undergoing antibiotic therapy.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: BU002
Participants will received BU002 as debridement treatment.
|
BU002 is a composition intended for debridement and antibiofilm in wounds.
Autres noms:
|
|
Comparateur actif: Polihexanide Gel
Participants will received Polihexanide gel as debridement treatment.
|
Polihexanide combined with betaine is a debridement and antibiofilm comercial product.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in wound area
Délai: Baseline, 4 weeks
|
The total wound area it will be measure by an image software (Ekare Insight)
|
Baseline, 4 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in wound area covered by slough and necrotic tissue
Délai: Baseline, 4 weeks
|
The area will be measured by an image software (Ekare Insight)
|
Baseline, 4 weeks
|
|
Change in wound bacterial load
Délai: Baseline, 4 weeks
|
The bacterial burden will be measure by swab sampling, then culturing to determine colony forming units.
|
Baseline, 4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2024-77
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .